{
    "organizations": [],
    "uuid": "39fb1c8756fd219c20dc35976e4df6281c64a6b4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-heron-therapeutics-says-enrollment/brief-heron-therapeutics-says-enrollment-complete-in-both-pivotal-phase-3-studies-for-htx-011-idUSFWN1P30M0",
    "ord_in_thread": 0,
    "title": "BRIEF-Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Heron Therapeutics Inc:\n* HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018\n* HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:57:00.000+02:00",
    "crawled": "2018-01-09T17:05:23.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "heron",
        "therapeutic",
        "inc",
        "heron",
        "therapeutic",
        "enrollment",
        "complete",
        "pivotal",
        "phase",
        "study",
        "result",
        "expected",
        "h1",
        "heron",
        "therapeutic",
        "inc",
        "phase",
        "efficacy",
        "study",
        "bunionectomy",
        "hernia",
        "repair",
        "expects",
        "file",
        "nda",
        "fda",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}